Global Acromegaly Treatment Market Size, Share, Growth Analysis, By Product(Somatostatin analogs, GHRA), By End-use(Hospitals & clinics, and Others) - Industry Forecast 2024-2031

Q: What is the key market trend for Global Acromegaly Treatment Market?

Increasing Focus on Targeted Therapies: The acromegaly treatment market has witnessed a shift towards targeted therapies, such as somatostatin analogs and growth hormone receptor antagonists. These therapies specifically target the underlying hormonal imbalance and offer improved efficacy and tolerability compared to traditional treatment options.

Report ID: SQMIG35I2170 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 62 | Figures: 75

Global Acromegaly Treatment Market Dynamics

Drivers

Increasing Prevalence of Acromegaly

The growing prevalence of acromegaly, a rare hormonal disorder caused by excessive growth hormone production, is a significant driver for the acromegaly treatment market. As awareness and diagnosis of the condition improve, there is an increasing demand for effective treatment options.

Restraints

Limited Awareness and Underdiagnosis

Despite the increasing prevalence of acromegaly, the condition often goes undiagnosed or is diagnosed late due to its slow onset and non-specific symptoms. Limited awareness among healthcare professionals and the general population about acromegaly hampers early diagnosis and timely treatment initiation, acting as a restraint for market growth.

Global Acromegaly Treatment Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Acromegaly Treatment Market size was valued at USD 1.49 Billion in 2021 and is poised to grow from 1.60 Billion in 2022 to 2.87 Billion by 2030, at a CAGR of 7.5% during the forecast period (2023-2030).

The competitive landscape in the acromegaly treatment market is characterized by the presence of several pharmaceutical companies, research institutions, and healthcare organizations. These players strive to develop innovative treatment options, expand their product portfolios, and establish strong market positions. These companies engage in strategic initiatives, such as mergers and acquisitions, collaborations, and product launches, to strengthen their market presence and gain a competitive edge. They also invest in research and development activities to develop novel treatment options and address the unmet needs of acromegaly patients. It's important to note that the competitive landscape may evolve over time, and there may be additional players in the market beyond the ones listed above. 'Pfizer Inc.', 'Novartis International AG', 'Ipsen Pharma', 'F. Hoffmann-La Roche Ltd.', 'Merck & Co., Inc.', 'Chiasma, Inc.', 'Amryt Pharma', 'Crinetics Pharmaceuticals, Inc.', 'Dauntless Pharmaceuticals, Inc.', 'Strongbridge Biopharma plc', 'Antisense Therapeutics Limited', 'Ionis Pharmaceuticals, Inc.', 'Clinigen Group plc', 'Ascendis Pharma A/S', 'Pfizer Inc.', 'Novartis International AG', 'Ipsen Pharma', 'F. Hoffmann-La Roche Ltd.', 'Merck & Co., Inc.', 'Chiasma, Inc.'

The growing prevalence of acromegaly, a rare hormonal disorder caused by excessive growth hormone production, is a significant driver for the acromegaly treatment market. As awareness and diagnosis of the condition improve, there is an increasing demand for effective treatment options.

Increasing Focus on Targeted Therapies: The acromegaly treatment market has witnessed a shift towards targeted therapies, such as somatostatin analogs and growth hormone receptor antagonists. These therapies specifically target the underlying hormonal imbalance and offer improved efficacy and tolerability compared to traditional treatment options.

North America had the largest revenue share in 2022 as a result of the condition's increasing prevalence and favorable governmental regulations. According to a study by the U.S. Endocrine Society, acromegaly impacted 40 to 125 persons per million people. Regional demand is also predicted to rise as a result of the expansion of important enterprises' concerted efforts to develop unique formulae and provide high-quality products. For instance, the phase 2 clinical study for BIM23B065 from Ipsen Pharma is now complete, and the phase 3 trial is being prepared.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Acromegaly Treatment Market Size, Share, Growth Analysis, By Product(Somatostatin analogs, GHRA), By End-use(Hospitals & clinics, and Others) - Industry Forecast 2024-2031

Global Acromegaly Treatment Market Dynamics

Global Acromegaly Treatment Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Acromegaly Treatment Market?

Who are the key vendors in the Global Acromegaly Treatment Market?

What is the key driver of Global Acromegaly Treatment Market?

What is the key market trend for Global Acromegaly Treatment Market?

Which region accounted for the largest share in Global Acromegaly Treatment Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300